|
Synonyms: GNC 038 | GNC-038 | GNC038
Compound class:
Antibody
Comment: Emfizatamab (GNC-038) is a humanized immunotherapeutic monoclonal antibody that is engineered to engage 4 molecular targets (tetra-specific), to provide immunostimulatory and antineoplastic activities as an approach to treat B cell malignancies. The protein targets are CD19, CD3e, PD-L1 and 4-1BB. Emfizatamab is designed to crosslink CD19-expressing tumour B cells with cytotoxic T lymphocytes (via CD3e binding). It also targets PD-L1 on the tumour cells (preventing interaction with the inhibitory T cell checkpoint protein PD-1), and engagement of 4-1BB (TNFRSF9) acts as a co-stimulatory signal on T cells that is proposed to enhance anti-tumour activity. Likely one of the so-called 'guidance and navigation control (GNC)' proteins that are claimed in Sichuan Baili Pharmaceutical/Systimmune patent US20210024630A1 [1].
|
| References |
|
1. Zhu Y, Olsen O, Xia D, Jellyman D, Bykova K, Rousseau AM, Brady B, Renshaw B, Kovacevich B, Liang Y et al.. (2021)
Guidance and navigation control proteins and method of making and using thereof. Patent number: US20210024630A1. Assignee: Baili Bio Chengdu Pharmaceutical Co Ltd Sichuan Baili Pharmaceutical Co Ltd, Systimmune Inc. Priority date: 27/03/2018. Publication date: 28/01/2021. |
